专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009046198A2 SUSTAINED DELIVERY OF COMPSTATIN ANALOGS FROM GELS 审中-公开
标题翻译：保持从凝胶中输送共聚物模拟物
公开(公告)号：WO2009046198A2
公开(公告)日：2009-04-09
申请号：PCT/US2008/078593
申请日：2008-10-02
申请人： POTENTIA PHARMACEUTICALS, INC. , FRANCOIS, Cedric , DESCHATELETS, Pascal , OLSON, Paul
发明人： FRANCOIS, Cedric , DESCHATELETS, Pascal , OLSON, Paul
IPC分类号： A61K9/10 , A61K9/52
CPC分类号： A61K9/0051 , A61K38/12 , A61K47/42
摘要： The present invention features the sustained delivery of compstatin analog and, optionally, an additional active agent, by release from a macroscopic, gel-like deposit formed by administering a liquid solution containing the compstatin analog to an extravascular location in the body of a mammalian subject such as the vitreous chamber.
摘要翻译：本发明的特征在于通过从包含化合物抑制物类似物的液体溶液施用于哺乳动物受试者体内的血管外位置形成的宏观的凝胶状沉积物释放，持续递送化合物类似物和任选的另外的活性剂如玻璃体腔。

2. 发明申请

WO2010135717A2 COMPLEMENT ASSAYS AND USES THEREOF 审中-公开
标题翻译：补充测定及其用途
公开(公告)号：WO2010135717A2
公开(公告)日：2010-11-25
申请号：PCT/US2010/035871
申请日：2010-05-21
申请人： POTENTIA PHARMACEUTICALS, INC. , ZHANG, Zhouning , FRANCOIS, Cedric , DESCHATELETS, Pascal , OLSON, Paul
发明人： ZHANG, Zhouning , FRANCOIS, Cedric , DESCHATELETS, Pascal , OLSON, Paul
IPC分类号： G01N33/53 , G01N33/577 , C07K16/18
CPC分类号： G01N33/566 , C07K16/18 , G01N33/564 , G01N33/6893 , G01N2333/4716 , G01N2800/16 , G01N2800/164 , G01N2800/50 , G01N2800/52 , G01N2800/7042
摘要： The present invention provides methods for assessing complement activation and methods for assessing the ability of an agent or condition of interest to modulate complement activation. The present invention provides methods for assessing whether a subject has or is at increased risk of developing a complement-mediated disorder, e.g., age-related macular degeneration (AMD). Also provided are kits containing materials useful for performing the methods.
摘要翻译：本发明提供了用于评估补体活化的方法和评估感兴趣的药剂或病症调节补体活化能力的方法。本发明提供用于评估受试者是否具有发生补体介导的病症（例如年龄相关性黄斑变性（AMD））的风险增加的方法。还提供了包含用于执行方法的材料的试剂盒。

3. 发明申请

WO2009015087A2 COMPOSITIONS AND METHODS FOR TREATMENT OF TRAUMA 审中-公开
标题翻译：用于治疗创伤的组合物和方法
公开(公告)号：WO2009015087A2
公开(公告)日：2009-01-29
申请号：PCT/US2008/070650
申请日：2008-07-21
申请人： POTENTIA PHARMACEUTICALS, INC. , FRANCOIS, Cedric , DESCHATELETS, Pascal , OLSON, Paul
发明人： FRANCOIS, Cedric , DESCHATELETS, Pascal , OLSON, Paul
IPC分类号： A61K38/00 , A61K39/39 , C07K7/08
CPC分类号： A61K38/12 , C12Q1/6883 , C12Q2600/106 , C12Q2600/136 , C12Q2600/156
摘要： The present invention features the use of a complement inhibitor, e.g., a compstatin analog for treating an individual who has suffered a severe injury. In some embodiments, the complement inhibitor may be administered within 24 hours following the injury and optionally also at later time points. The complement inhibitor may, for example, be administered prior to transporting the patient to a health care facility, during transport of the patient to a health care facility, or in the emergency department. Further provided are methods of selecting individuals for such therapy. Further provided are methods of identifying individuals at increased risk of poor outcome following trauma. In certain embodiments the methods comprise determining whether the genotype of the patient includes an allele of a polymorphism in or near a complement-related gene, wherein said allele is associated with risk of poor outcome following trauma.
摘要翻译：本发明的特征在于补体抑制剂例如坎普他汀类似物用于治疗遭受严重损伤的个体的用途。在一些实施方案中，补体抑制剂可以在损伤后24小时内施用，并任选地在稍后的时间点施用。例如，补体抑制剂可以在将患者运输到健康护理设施之前，在将患者运送到健康护理设施期间或在急诊室中进行施用。还提供了选择用于这种治疗的个体的方法。进一步提供了鉴定创伤后不良结局风险增加的个体的方法。在某些实施方案中，所述方法包括确定患者的基因型是否在补体相关基因中或附近包含多态性的等位基因，其中所述等位基因与创伤后不良结果的风险相关。

4. 发明申请

WO2007044668A3 COMPSTATIN AND ANALOGS THEREOF FOR EYE DISORDERS 审中-公开
公开(公告)号：WO2007044668A3
公开(公告)日：2007-04-19
申请号：PCT/US2006/039397
申请日：2006-10-06
申请人： POTENTIA PHARMACEUTICALS, INC. , DESCHATELETS, Pascal , OLSON, Paul , FRANCOIS, Cedric
发明人： DESCHATELETS, Pascal , OLSON, Paul , FRANCOIS, Cedric
IPC分类号： A61K38/08 , A61K38/10 , A61P27/02
摘要： The present invention features the use of compstatin and complement inhibiting analogs thereof for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration, choroidal neovascularization, and/or retinal neovascularization. The invention also provides compositions comprising compstatin or a complement inhibiting analog thereof and a second therapeutic agent. The invention also provides compositions comprising compstatin or a complement inhibiting analog thereof and a gel-forming material, e.g., soluble collagen, and methods of administering the compositions.

5. 发明申请

WO2005019429A2 COMPOSITIONS AND METHODS FOR ENHANCING PHAGOCYTOSIS OR PHAGOCYTE ACTIVITY 审中-公开
标题翻译：用于增强PHAGOCYTOSIS或PHAGOCYTE活性的组合物和方法
公开(公告)号：WO2005019429A2
公开(公告)日：2005-03-03
申请号：PCT/US2004/027245
申请日：2004-08-23
申请人： POTENTIA PHARMACEUTICALS, INC. , FRANCOIS, Cedric , OLSON, Paul , DESCHATELETS, Pascal , MACHIELS, Alec
发明人： FRANCOIS, Cedric , OLSON, Paul , DESCHATELETS, Pascal , MACHIELS, Alec
IPC分类号： C12N
CPC分类号： B82Y5/00 , A61K47/544 , A61K47/62 , A61K47/6911 , A61K47/6913
摘要： The present invention provides a system for enhancing clearance or destruction of undesirable cells or noncellular molecular entities by tagging such cells or noncellular molecular entities with a marker that targets the cells or noncellular molecular entities for phagocytosis (phagocytic marker). The target cells can be, for example, endothelial cells, tumor cells, leukocytes, or virus-infected cells. In certain embodiments of the invention the tagging is accomplished by administering a composition comprising an antibody or ligand linked to the phagcytotic marker, wherein the antibody or ligand binds to a cell type specific marker present on or in the cell surface of a target cell. In preferred embodiments of the invention, the phagocytic marker comprises phosphatidylserine or a group derived from phosphatidylserine, thrombospondin-1, annexin I, or a derivative of any of these.
摘要翻译：本发明提供了一种用于通过用靶向细胞或非细胞分子实体进行吞噬作用（吞噬标记）的标记来标记这样的细胞或非细胞分子实体来增强不需要的细胞或非细胞分子实体的清除或破坏的系统。靶细胞可以是例如内皮细胞，肿瘤细胞，白细胞或病毒感染的细胞。在本发明的某些实施方案中，标记通过施用包含与噬菌体标记物连接的抗体或配体的组合物来实现，其中所述抗体或配体结合存在于靶细胞的细胞表面上或细胞表面的细胞类型特异性标志物。在本发明的优选实施方案中，吞噬标记物包含磷脂酰丝氨酸或衍生自磷脂酰丝氨酸，血小板反应素-1，膜联蛋白I或其任何衍生物的基团。

6. 发明申请

WO2008097525A2 LOCAL COMPLEMENT INHIBITION FOR TREATMENT OF COMPLEMENT-MEDIATED DISORDERS 审中-公开
标题翻译：用于治疗补充介入性疾病的局部补充抑制
公开(公告)号：WO2008097525A2
公开(公告)日：2008-08-14
申请号：PCT/US2008/001483
申请日：2008-02-05
申请人： POTENTIA PHARMACEUTICALS, INC. , FRANCOIS, Cedric , DESCHATELETS, Pascal , OLSON, Paul
发明人： FRANCOIS, Cedric , DESCHATELETS, Pascal , OLSON, Paul
CPC分类号： A61K39/3955 , A61K38/12 , A61K38/17 , A61K45/06 , C07K7/64 , C07K14/435
摘要： The present invention features the local administration of complement inhibitors for treatment of complement-mediated disorders. In certain embodiments the invention features inhibiting activation of one or more locally produced complement proteins. The invention provides sustained release formulations and devices comprising a complement inhibitor and methods of use thereof.
摘要翻译：本发明的特征在于用于治疗补体介导的病症的补体抑制剂的局部施用。在某些实施方案中，本发明特征在于抑制一种或多种局部产生的补体蛋白的活化。本发明提供持续释放制剂和包含补体抑制剂的装置及其使用方法。

7. 发明申请

WO2006099330A2 COMPOSITIONS AND METHODS FOR TREATMENT OF MACULAR DEGENERATION AND RELATED CONDITIONS 审中-公开
标题翻译：用于治疗谷物变性和相关条件的组合物和方法
公开(公告)号：WO2006099330A2
公开(公告)日：2006-09-21
申请号：PCT/US2006/008960
申请日：2006-03-13
申请人： POTENTIA PHARMACEUTICALS, INC. , DESCHATELETS, Pascal , FRANCOIS, Cedric
发明人： DESCHATELETS, Pascal , FRANCOIS, Cedric
CPC分类号： A61K38/005 , A61L27/227
摘要： The present invention provides methods and compositions for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration, ocular neovascularization, or ocular inflammation. The methods comprise administering a composition comprising a compound that is an antagonist of a G protein coupled receptor, e.g., the C5a receptor, to a subject in need of treatment or prevention of age-related macular degeneration or another condition involving macular degeneration or ocular neovascularization. The invention provides compositions comprising a compound that is an antagonist of a G protein coupled receptor linked either directly or indirectly to a moiety that binds to a component present on or at the surface of cell or noncellular molecular entity, e.g., a component present in the eye of a subject at risk of or suffering from age related macular degeneration or a related condition or choroidal neovascularization.
摘要翻译：本发明提供用于治疗和/或预防年龄相关性黄斑变性和涉及黄斑变性，眼新生血管形成或眼部炎症的其它病症的方法和组合物。所述方法包括向需要治疗或预防年龄相关性黄斑变性的受试者或涉及黄斑变性或眼新生血管形成的另一种病症施用包含作为G蛋白偶联受体的拮抗剂的化合物（例如C5a受体）的组合物。本发明提供了包含化合物的组合物，其是G蛋白偶联受体的拮抗剂，其直接或间接地连接到与存在于细胞或非细胞分子实体上或其表面上的组分结合的部分，例如存在于患有年龄相关性黄斑变性或相关病症或脉络膜新生血管形成危险的患者的眼睛。

8. 发明申请

WO2007084765A3 INJECTABLE COMBINATION THERAPY FOR EYE DISORDERS 审中-公开
公开(公告)号：WO2007084765A3
公开(公告)日：2007-07-26
申请号：PCT/US2007/001649
申请日：2007-01-19
申请人： POTENTIA PHARMACEUTICALS, INC. , DESCHATELETS, Pascal , OLSON, Paul
发明人： DESCHATELETS, Pascal , OLSON, Paul
IPC分类号： A61P27/02 , A61F2/14 , A61K47/06 , A61K39/395 , A61K38/17 , A61K31/00 , A61K9/00
摘要： The present invention provides composition, methods, and articles of manufacture for treating an eye disorder, e.g., a disorder characterized by macular degeneration, choroidal neovascularization, or retinal neovascularization. One method of the invention comprises the step of: administering first and second therapeutic agents to the subject's eye in a single procedure, wherein the first therapeutic agent provides rapid improvement in the condition of the subject's eye and the second therapeutic agent is administered as a sustained release formulation of the second therapeutic agent. For example, the first and second therapeutic agents are administered by intravitreal injection. The first therapeutic agent may be dissolved in a liquid medium located in the syringe and the sustained formulation of the second therapeutic agent may comprise an ocular implant or plurality of particles located in the needle. The therapeutic agents may be selected from the group consisting of angiogenesis inhibors and complement inhibitors.

9. 发明申请

WO2009121065A2 MODULATION AND REPLETION/ENHANCEMENT OF THE COMPLEMENT SYSTEM FOR TREATMENT OF TRAUMA 审中-公开
标题翻译： TRAUMA治疗补充系统的调整和复制/增强
公开(公告)号：WO2009121065A2
公开(公告)日：2009-10-01
申请号：PCT/US2009/038807
申请日：2009-03-30
申请人： APELLIS AG , FRANCOIS, Cedric , DESCHATELETS, Pascal , OLSON, Paul
发明人： FRANCOIS, Cedric , DESCHATELETS, Pascal , OLSON, Paul
IPC分类号： A61K38/10 , A61P25/18 , A61K39/395 , A61K38/08 , A61K38/16
CPC分类号： A61K9/0019 , A61K38/12 , A61K38/162 , A61K38/1725 , A61K38/177
摘要： The present invention features the use of selected complement activation inhibitor(s) for treating an individual who has suffered a severe injury. The complement activation inhibitor acts at or above the level of C3 activation and does not significantly deplete or irreversibly inhibit complement activation. Also provided are compositions and methods for repleting and/or enhancing complement activation capacity in a subject who has suffered a traumatic injury.
摘要翻译：本发明的特征在于使用选择的补体活化抑制剂来治疗遭受严重损伤的个体。补体激活抑制剂起作用或高于C3激活水平，并且不显着消耗或不可逆地抑制补体活化。还提供了在遭受创伤性损伤的受试者中补充和/或增强补体活化能力的组合物和方法。

10. 发明申请

WO2006042252A2 VIRAL COMPLEMENT CONTROL PROTEINS FOR EYE DISORDERS 审中-公开
标题翻译：眼睛疾病的病毒补体控制蛋白
公开(公告)号：WO2006042252A2
公开(公告)日：2006-04-20
申请号：PCT/US2005/036547
申请日：2005-10-08
申请人： POTENTIA PHARMECEUTICALS, INC. , FRANCOIS, Cedric , DESCHATELETS, Pascal , OLSON, Paul
发明人： FRANCOIS, Cedric , DESCHATELETS, Pascal , OLSON, Paul
CPC分类号： A61K38/162 , C07K14/005 , C07K2319/33 , C12N2710/24122
摘要： The present invention provides compositions and methods for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration or choroidal neovascularization. Certain of the compositions comprise a poxvirus complement control protein or a complement binding fragment or variant thereof. Other compositions comprise a poxvirus complement control protein linked to a moiety that binds to a component present on or at the surface of cell or noncellular molecular entity, e.g., a component present in the eye of a subject at risk of or suffering from age related macular degeneration or a related condition or choroidal neovascularization. Certain of the methods comprise administering a poxvirus complement control protein or complement binding fragment or variant thereof to a subject.
摘要翻译：本发明提供用于治疗和/或预防年龄相关性黄斑变性和涉及黄斑变性或脉络膜新生血管形成的其它病症的组合物和方法。某些组合物包含痘病毒补体对照蛋白或其补体结合片段或变体。其他组合物包含与结合存在于细胞或非细胞分子实体的表面或其表面上的组分连接的部分的痘病毒补体对照蛋白，例如存在于患有年龄相关性黄斑的风险的患者的眼睛中的组分变性或相关病症或脉络膜新生血管形成。某些方法包括向受试者施用痘病毒补体对照蛋白或补体结合片段或其变体。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式